Milbemycin/Lufenuron Tablets
3,628 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 3,628 |
| Reports involving death | 53 |
| Case-fatality rate (reported events) | 150.0% |
| Distinct species in reports | 3 |
| Distinct breeds in reports | 20 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 1 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Milbemycin/Lufenuron Tablets Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 3,628 adverse event reports referencing Milbemycin/Lufenuron Tablets, including 53 reports in which the animal died — a 150.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Milbemycin/Lufenuron Tablets. Reported administration routes include Oral, Unknown, Topical, Iontophoresis. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Milbemycin/Lufenuron Tablets reports are Dog (3,501 reports), Unknown (120 reports), Human (7 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (987), Retriever - Labrador (380), Retriever - Golden (159) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Milbemycin/Lufenuron Tablets are Lack of efficacy (endoparasite) - heartworm (1,386), Lack of efficacy (endoparasite) - hookworm (552), Vomiting (310), Lack of efficacy (endoparasite) - roundworm NOS (301). Of the 3,510 reports with a coded outcome, Ongoing is the leading category at 76.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Milbemycin/Lufenuron Tablets.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.